Azalea A Fib

The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.

This trial is currently in follow-up and is not accepting new patients. To be considered for similar trials, please complete the form below.